| abstract |
(57) SUMMARY The present invention is directed to dihydropyrimidines, which are selective antagonists of the human α 1A receptor. The invention also relates to the use of these compounds for relaxing the lower urethra tissue, for treating benign prostatic hyperplasia, and for treating any disease in which antagonism of the α1A receptor may be useful. The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above compound and a pharmaceutically acceptable carrier. |